Biomea Fusion, Inc. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
Biomea Fusion, Inc. (BMEA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.44 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-08-05
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2025-03-31 was $2.53, a 82.67% decline year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $14.60, a 88.14% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $7.76, a 18.65% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $6.54, a 1.08% increase year-over-year.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.75, a 86.69% decline from fiscal 2024.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $13.15, a 23.36% increase from fiscal 2023.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $10.66, a 55.39% increase from fiscal 2022.
- Biomea Fusion, Inc. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $6.86, a 30.00% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.44 10-Q · filed 2026-08-05 | |||
| 2025-12-31 | $1.75 10-K · filed 2026-03-24 | |||
| 2025-09-30 | $1.74 10-Q · filed 2025-11-04 | |||
| 2025-06-30 | $2.49 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $2.53 10-Q · filed 2025-05-05 | |||
| 2024-12-31 | $13.15 10-K · filed 2025-03-31 | |||
| 2024-09-30 | $13.27 10-Q · filed 2024-10-29 | |||
| 2024-06-30 | $13.29 10-Q · filed 2024-07-31 | |||
| 2024-03-31 | $14.60 10-Q · filed 2024-05-02 | |||
| 2023-12-31 | $10.66 10-K · filed 2024-03-28 | |||
| 2023-09-30 | $10.54 10-Q · filed 2023-10-30 | |||
| 2023-06-30 | $9.17 10-Q · filed 2023-07-31 | |||
| 2023-03-31 | $7.76 10-Q · filed 2023-05-02 | |||
| 2022-12-31 | $6.86 10-K · filed 2023-03-28 | |||
| 2022-09-30 | $6.39 10-Q · filed 2022-11-07 | |||
| 2022-06-30 | $5.65 10-Q · filed 2022-08-01 | |||
| 2022-03-31 | $6.54 10-Q · filed 2022-05-16 | |||
| 2021-12-31 | $9.80 10-K · filed 2022-02-28 | |||
| 2021-09-30 | $9.79 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $17.89 10-Q · filed 2021-08-11 | |||
| 2021-03-31 | $6.47 10-Q · filed 2021-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Polaryx Therapeutics, Inc. (PLYX) | United States | $0.106B | |
| Equillium, Inc. (EQ) | United States | $0.109B | -11.27 |
| GENELUX Corp (GNLX) | United States | $0.110B | -3.83 |
| BICYCLE THERAPEUTICS PLC (BCYC) | $0.112B | -1.56 | |
| ProMIS Neurosciences Inc. (PMN) | $0.102B | ||
| Quantum Cyber N.V. (QUCY) | $0.113B | ||
| Immuneering Corp (IMRX) | United States | $0.113B | -12.51 |
| Milestone Pharmaceuticals Inc. (MIST) | $0.098B | -2.00 | |
| CITIUS ONCOLOGY, INC. (CTOR) | United States | $0.097B | -1.49 |
| Anixa Biosciences Inc (ANIX) | United States | $0.096B |